pipette
ESEspañol

Use of split intein and myotropic AAV vectors enables effective preclinical gene therapy for dysferlinopathy

Nikki M. McCormack, Stephanie Lee-Diaz, Theodore R. Reyes, Marshall W. Hogarth, Jada L. Covington, Camryn A. Bragg, Zarek O Harper, Thomas Diehn, James S. Novak, Christine L. Halbert, Jeffrey S. Chamberlain, David L. Mack, Martin K. Childers, Jyoti K. Jaiswal, Hichem Tasfaout

Peer-reviewed journalBold claims, read criticallyReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Systemic administration of split-intein and dysferlin dual AAVMYO1 vectors improved muscle strength, increased contractile force, and reduced histopathological abnormalities in the LGMDR2 mouse model at both the presymptomatic stage and late stage of the disease.

Appeared: Friday, October 9. Science Translational Medicine. Peer-reviewed journal.

DOI: 10.1126/scitranslmed.aei5938